Alvotech to Report Financial Results for H1 2026

REYKJAVIK,  ICELAND (August 10, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, August 20, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST).

GlobeNewsWire • Aug 10, 2026

Alvotech announces successful closure of FDA inspection of manufacturing facility

REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has closed its inspection of the company's manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA has confirmed the inspection classification of the manufacturing site is Voluntary Action Indicated (VAI).

GlobeNewsWire • Jul 29, 2026

Transactions of Managers and Closely Associated Persons

Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the pledging of (i) 88,940,619 shares and (ii) 7,007,321 depository receipts on shares in Alvotech by Celtic Lux Holdings S.a. r.l. (formerly known as Alvogen Lux Holdings S.a. r.l.). The date of the transactions was June 26, 2026.

GlobeNewsWire • Jul 3, 2026

Alvotech further strengthens liquidity by securing term loan facility of $75 million

REYKJAVIK, ICELAND (July 1, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has amended its existing credit agreement with funds managed by GoldenTree Asset Management LP and other existing lenders of Alvotech to provide a term loan facility of up to $75 million in additional capital.

GlobeNewsWire • Jul 1, 2026

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has commenced an underwritten public offering of its ordinary shares (the “Offering”). In addition, Alvotech expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering at the public offering price, less underwriting discounts and commissions.

GlobeNewsWire • Jun 18, 2026

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

REYKJAVIK,  ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech.

GlobeNewsWire • Jun 18, 2026

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

REYKJAVIK,  ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech.

GlobeNewsWire • Jun 16, 2026

Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions

Alvotech NASDAQ: ALVO Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through regulatory review and prepares for a broader launch cycle over the next several years.

MarketBeat • Jun 10, 2026

Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day Transcript

Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day Transcript

Seeking Alpha • Jun 10, 2026

Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026